Prognostic value of pericoronary adipose tissue attenuation in cardiovascular outcomes: a systematic review and meta-analysis.

Eur J RadiolAug 26, 2026 (epub)
Clinical ResearchCardiology

Ren Isaka, Shingo Kato, Nobuyuki Horita et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of pericoronary adipose tissue (PCAT) attenuation in predicting major adverse cardiovascular events (MACE) and mortality across diverse populations. Analyzing 21 studies with 17,160 patients, the results indicated that elevated PCAT attenuation significantly increased the risk of MACE (HR 1.58), all-cause mortality (HR 1.77), and cardiac mortality (HR 2.25).

Key findings

  • Elevated PCAT attenuation was associated with MACE (HR 1.58; 95% CI: 1.38-1.81, p < 0.001).
  • All-cause mortality was linked to higher PCAT attenuation (HR 1.77; 95% CI: 1.51-2.07, p < 0.001).
  • Cardiac mortality showed a significant association with elevated PCAT attenuation (HR 2.25; 95% CI: 1.62-3.13, p < 0.001).
  • Measurement method and body mass index were identified as potential effect modifiers.

Why it matters

Understanding the prognostic significance of PCAT attenuation can aid clinicians in assessing cardiovascular risk and tailoring management strategies. This biomarker may enhance risk stratification in patients with coronary artery disease.

Source

PubMed · PMID 42659900

Published in Eur J Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.